Insulet PODD Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $2.71B+30.7% | $2.07B+22.1% | $1.7B+30.0% | $1.31B+18.8% | ||
| $768.2M+22.7% | $625.9M+16.5% | $537.2M+7.5% | $499.7M+44.1% | ||
| $1.94B+34.2% | $1.45B+24.6% | $1.16B+44.0% | $805.6M+7.1% | ||
| 71.6%+1.8pp | 69.8%+1.4pp | 68.3%+6.6pp | 61.7%-6.7pp | ||
| $301.1M+37.1% | $219.6M+7.1% | $205M+13.8% | $180.2M+12.6% | ||
| $1.17B+27.0% | $917.2M+24.8% | $734.8M+25.0% | $587.8M+26.1% | ||
| $473.9M+53.5% | $308.8M+40.3% | $220.1M+485% | $37.6M-70.2% | ||
| 17.5%+2.6pp | 14.9%+1.9pp | 13%+10.1pp | 2.9%-8.6pp | ||
| $59.3M+38.9% | $42.7M+18.0% | $36.2M— | —— | ||
| $14.3M+342% | -$5.9M-368% | $2.2M— | —— | ||
| $339.6M+13.1% | $300.3M+39.9% | $214.7M+2,091% | $9.8M-52.2% | ||
| $92.3M+172% | -$128.7M-1,651% | $8.3M+59.6% | $5.2M+40.5% | ||
| $247.1M-40.9% | $418.3M+103% | $206.3M+4,385% | $4.6M-72.6% | ||
| 9.1%-11.1pp | 20.2%+8.0pp | 12.2%+11.8pp | 0.4%-1.2pp | ||
| $3.49-39.6% | $5.78+96.6% | $2.94+4,100% | $0.07-69.6% | ||
| $564.3M+44.8% | $389.6M+33.0% | $292.9M+191% | $100.8M-45.0% | ||
| 20.8%+2.0pp | 18.8%+1.5pp | 17.3%+9.5pp | 7.7%-9.0pp | ||
| $473.9M+53.5% | $308.8M+40.3% | $220.1M+485% | $37.6M-70.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Insulet's revenue?
- Insulet (PODD) generated $2.9B in revenue over the trailing twelve months, up 31.9% year over year.
- Is Insulet profitable?
- Insulet reported $302.8M in net income over the trailing twelve months, a 10.4% net margin.
- What are Insulet's profit margins?
- Gross margin is 71.0% and operating margin is 17.5%, with a 10.4% net margin.
- What is Insulet's earnings per share?
- Insulet's diluted EPS over the trailing twelve months is $4.29.
- Where does Insulet's income statement data come from?
- Every line is extracted from Insulet's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
